Multidisciplinary Cardiovascular Annals

Published by: Kowsar

Giant Cell Myocarditis: Case Review

Meysam Khoshavi 1 , Ahmad Amin 1 , * , Mousa Youssef 1 , Sepideh Taghavi 1 , Nasim Naderi 1 , Iman Divanbeigi 2 , Shabnam Madadi 1 , Majid Haghjoo 1 and Zahra Emkanjoo 1
Authors Information
1 Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
2 Mostofi Pathology Center, Tehran, Iran
Article information
  • Multidisciplinary Cardiovascular Annals: July 2018, 9 (2); e80901
  • Published Online: September 17, 2018
  • Article Type: Case Report
  • Received: June 16, 2018
  • Revised: August 29, 2018
  • Accepted: September 10, 2018
  • DOI: 10.5812/mca.80901

To Cite: Khoshavi M, Amin A, Youssef M, Taghavi S, Naderi N, et al. Giant Cell Myocarditis: Case Review, Multidiscip Cardio Annal. 2018 ; 9(2):e80901. doi: 10.5812/mca.80901.

Copyright © 2018, Multidisciplinary Cardiovascular Annals. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Case Presentation
3. Discussion
  • 1. Okura Y, Dec GW, Hare JM, Kodama M, Berry GJ, Tazelaar HD, et al. A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis. J Am Coll Cardiol. 2003;41(2):322-9. [PubMed: 12535829].
  • 2. Kalra A, Kneeland R, Samara MA, Cooper LT Jr. The changing role for endomyocardial biopsy in the diagnosis of giant-cell myocarditis. Cardiol Ther. 2014;3(1-2):53-9. doi: 10.1007/s40119-014-0028-5. [PubMed: 25135591]. [PubMed Central: PMC4265228].
  • 3. Kandolin R, Lehtonen J, Kupari M. Cardiac sarcoidosis and giant cell myocarditis as causes of atrioventricular block in young and middle-aged adults. Circ Arrhythm Electrophysiol. 2011;4(3):303-9. doi: 10.1161/CIRCEP.110.959254. [PubMed: 21427276].
  • 4. Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, et al. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol. 2009;53(17):1475-87. doi: 10.1016/j.jacc.2009.02.007. [PubMed: 19389557]. [PubMed Central: PMC2743893].
  • 5. Okada R, Wakafuji S. Myocarditis in autopsy. Heart Vessels Suppl. 1985;1:23-9. [PubMed: 2956238].
  • 6. Kandolin R, Lehtonen J, Salmenkivi K, Raisanen-Sokolowski A, Lommi J, Kupari M. Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ Heart Fail. 2013;6(1):15-22. doi: 10.1161/CIRCHEARTFAILURE.112.969261. [PubMed: 23149495].
  • 7. Davidoff R, Palacios I, Southern J, Fallon JT, Newell J, Dec GW. Giant cell versus lymphocytic myocarditis. A comparison of their clinical features and long-term outcomes. Circulation. 1991;83(3):953-61. [PubMed: 1999043].
  • 8. Davies RA, Veinot JP, Smith S, Struthers C, Hendry P, Masters R. Giant cell myocarditis: Clinical presentation, bridge to transplantation with mechanical circulatory support, and long-term outcome. J Heart Lung Transplant. 2002;21(6):674-9. [PubMed: 12057701].
  • 9. Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis-natural history and treatment. Multicenter giant cell myocarditis study group investigators. N Engl J Med. 1997;336(26):1860-6. doi: 10.1056/NEJM199706263362603. [PubMed: 9197214].
  • 10. Caforio AL. Long term risk of recurrence, morbidity and mortality in giant cell myocarditis. Am J Cardiol. 2015.
  • 11. Cooper LT Jr, Hare JM, Tazelaar HD, Edwards WD, Starling RC, Deng MC, et al. Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol. 2008;102(11):1535-9. doi: 10.1016/j.amjcard.2008.07.041. [PubMed: 19026310]. [PubMed Central: PMC2613862].
  • 12. Cooper LT Jr. Giant cell myocarditis: Diagnosis and treatment. Herz. 2000;25(3):291-8. [PubMed: 10904855].
  • 13. Yoshida Y, Morimoto S, Hiramitsu S, Tsuboi N, Hirayama H, Itoh T. Incidence of cardiac sarcoidosis in Japanese patients with high-degree atrioventricular block. Am Heart J. 1997;134(3):382-6. [PubMed: 9327691].
  • 14. Banba K, Kusano KF, Nakamura K, Morita H, Ogawa A, Ohtsuka F, et al. Relationship between arrhythmogenesis and disease activity in cardiac sarcoidosis. Heart Rhythm. 2007;4(10):1292-9. doi: 10.1016/j.hrthm.2007.06.006. [PubMed: 17905334].
  • 15. Kadkhodayan A, Chareonthaitawee P, Raman SV, Cooper LT. Imaging of inflammation in unexplained cardiomyopathy. Cardiovas Imag. 2016;9(5):603-17. doi: 10.1016/j.jcmg.2016.01.010.
  • 16. Adam RD, Shambrook J, Flett AS. The prognostic role of tissue characterisation using cardiovascular magnetic resonance in heart failure. Card Fail Rev. 2017;3(2):86-96. doi: 10.15420/cfr.2017:19:1. [PubMed: 29387459]. [PubMed Central: PMC5739890].
  • 17. Xu J, Brooks EG. Giant cell myocarditis: A brief review. Arch Pathol Lab Med. 2016;140(12):1429-34. doi: 10.5858/arpa.2016-0068-RS. [PubMed: 27922771].
  • 18. Vaideeswar P, Cooper LT. Giant cell myocarditis: Clinical and pathological features in an Indian population. Cardiovasc Pathol. 2013;22(1):70-4. doi: 10.1016/j.carpath.2012.06.003. [PubMed: 22863545].
  • 19. Steger CM, Hofer D, Antretter H. Giant cell and granulomatous myocarditis necessitating cardiac transplantation: Clinical, gross, and histopathological findings. Euro Surg. 2014;46(5):209-15. doi: 10.1007/s10353-014-0269-5.
  • 20. Rosenstein ED, Zucker MJ, Kramer N. Giant cell myocarditis: Most fatal of autoimmune diseases. Semin Arthritis Rheum. 2000;30(1):1-16. doi: 10.1053/sarh.2000.8367. [PubMed: 10966208].
  • 21. Lagana SM, Parwani AV, Nichols LC. Cardiac sarcoidosis: A pathology-focused review. Arch Pathol Lab Med. 2010;134(7):1039-46. doi: 10.1043/2009-0274-RA.1. [PubMed: 20586635].
  • 22. Dennert R, Schalla S, Suylen RJ, Eurlings L, Heymans S. Giant cell myocarditis triggered by a parvovirus B19 infection. Int J Cardiol. 2009;134(1):115-6. doi: 10.1016/j.ijcard.2007.12.020. [PubMed: 18280593].
  • 23. Menghini VV, Savcenko V, Olson LJ, Tazelaar HD, Dec GW, Kao A, et al. Combined immunosuppression for the treatment of idiopathic giant cell myocarditis. Mayo Clin Proc. 1999;74(12):1221-6. [PubMed: 10593350].
  • 24. Grabmaier U, Brenner C, Methe H, Kaczmarek I, Schramm R, Klingel K, et al. An alternative immunosuppressive regimen to prolong transplant free survival in a patient with giant cell myocarditis. Int J Cardiol. 2013;168(1):e27-8. doi: 10.1016/j.ijcard.2013.05.078. [PubMed: 23735345].
  • 25. Frustaci A, Chimenti C, Pieroni M, Gentiloni N. Giant cell myocarditis responding to immunosuppressive therapy. Chest. 2000;117(3):905-7. [PubMed: 10713027].
  • 26. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147-239. doi: 10.1016/j.jacc.2013.05.019. [PubMed: 23747642].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments